Jimmy Elias
YOU?
Author Swipe
View article: Supplemental Figure 1 from Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination
Supplemental Figure 1 from Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination Open
Brain and flank tumors are of equivalent mass. Brain and flank tumor mass was not different on day 17 when tissues were harvested for analysis. Experiment conducted x 2 with {greater than or equal to} 5 mice/group.
View article: Supplemental Figure 3 from Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination
Supplemental Figure 3 from Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination Open
TGF-β blockade does not add to RT + vaccination. TGF-β blockade with 1D11 (A) or LY2157299 (B) does not extend survival when combined with RT + rLM-OVA in mice with B16-OVA brain tumors. (N= 10 animals / group).
View article: Supplemental Figure 2 from Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination
Supplemental Figure 2 from Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination Open
Brain tumors are more tolerogenic than flank or lung tumors. (A) Representative FACS plots from tumor draining lymph nodes of mice with B16-OVA brain, flank, or lung tumors. (B) Summary graphs of the percentage of daughter cells producing …
View article: Supplemental Figure 6 from Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination
Supplemental Figure 6 from Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination Open
B16-OVA brain tumors stimulate secretion of TGF-β1 from microglia. Cytokine concentrations in the supernatants from OT-1 cells co-cultured with (A) CD11c+ APCs isolated from the spleen at a ratio of 1:5, (B) APC from brain tumor draining l…
View article: Data from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
Data from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma Open
Purpose:[131I]meta-iodobenzylguanidine ([131I]MIBG) is a targeted radiotherapeutic administered systemically to deliver beta particle radiation in neuroblastoma. However, relapses in the bone marrow are common. […
View article: Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma Open
Supplementary Figure from Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
View article: Supplemental Figure 4 from Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination
Supplemental Figure 4 from Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination Open
: PD-1 blockade does not add to RT + Vaccination. Adding PD-1 blockade to RT + rLM-OVA does not significantly improve survival in mice with B16-OVA brain tumors. (N = 10 animals / group)
View article: Supplemental Figure 3 from Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination
Supplemental Figure 3 from Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination Open
TGF-β blockade does not add to RT + vaccination. TGF-β blockade with 1D11 (A) or LY2157299 (B) does not extend survival when combined with RT + rLM-OVA in mice with B16-OVA brain tumors. (N= 10 animals / group).
View article: Supplemental Figure 6 from Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination
Supplemental Figure 6 from Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination Open
B16-OVA brain tumors stimulate secretion of TGF-β1 from microglia. Cytokine concentrations in the supernatants from OT-1 cells co-cultured with (A) CD11c+ APCs isolated from the spleen at a ratio of 1:5, (B) APC from brain tumor draining l…
View article: Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma Open
Supplementary Figure from Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
View article: Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma Open
Supplementary Figure from Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
View article: Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma Open
Supplementary Figure from Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
View article: Supplemental Figure 5 from Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination
Supplemental Figure 5 from Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination Open
Tumor Morphology and Volume Upon Death. A) Morphology of tumors calculated using ex vivo MRI as described. B) Calculated brain tumor volumes at the time of death as determined by ex vivo MRI (N = 3 mice/group).
View article: Data from Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination
Data from Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination Open
Purpose: Immune responses to antigens originating in the central nervous system (CNS) are generally attenuated, as collateral damage can have devastating consequences. The significance of this finding for the efficacy of tumor-targe…
View article: Data from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
Data from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma Open
Purpose:[131I]meta-iodobenzylguanidine ([131I]MIBG) is a targeted radiotherapeutic administered systemically to deliver beta particle radiation in neuroblastoma. However, relapses in the bone marrow are common. […
View article: Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma Open
Supplementary Figure from Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
View article: Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma Open
Supplementary Figure from Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
View article: Supplemental Figure 1 from Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination
Supplemental Figure 1 from Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination Open
Brain and flank tumors are of equivalent mass. Brain and flank tumor mass was not different on day 17 when tissues were harvested for analysis. Experiment conducted x 2 with {greater than or equal to} 5 mice/group.
View article: Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma Open
Supplementary Figure from Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
View article: Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma Open
Supplementary Figure from Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
View article: Supplemental Figure 2 from Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination
Supplemental Figure 2 from Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination Open
Brain tumors are more tolerogenic than flank or lung tumors. (A) Representative FACS plots from tumor draining lymph nodes of mice with B16-OVA brain, flank, or lung tumors. (B) Summary graphs of the percentage of daughter cells producing …
View article: Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma Open
Supplementary Figure from Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
View article: Data from Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination
Data from Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination Open
Purpose: Immune responses to antigens originating in the central nervous system (CNS) are generally attenuated, as collateral damage can have devastating consequences. The significance of this finding for the efficacy of tumor-targe…
View article: Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma Open
Supplementary Figure from Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
View article: Supplemental Figure 5 from Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination
Supplemental Figure 5 from Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination Open
Tumor Morphology and Volume Upon Death. A) Morphology of tumors calculated using ex vivo MRI as described. B) Calculated brain tumor volumes at the time of death as determined by ex vivo MRI (N = 3 mice/group).
View article: Supplemental Figure 4 from Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination
Supplemental Figure 4 from Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination Open
: PD-1 blockade does not add to RT + Vaccination. Adding PD-1 blockade to RT + rLM-OVA does not significantly improve survival in mice with B16-OVA brain tumors. (N = 10 animals / group)
View article: Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma Open
Purpose: [131I]meta-iodobenzylguanidine ([131I]MIBG) is a targeted radiotherapeutic administered systemically to deliver beta particle radiation in neuroblastoma. However, relapses in the bone marrow are common. [211At]meta-astatobenzylgua…
View article: Limited antitumor activity of combined BET and MEK inhibition in neuroblastoma
Limited antitumor activity of combined BET and MEK inhibition in neuroblastoma Open
Background The treatment of high‐risk neuroblastoma continues to present a formidable challenge to pediatric oncology. Previous studies have shown that Bromodomain and extraterminal (BET) inhibitors can inhibit MYCN expression and suppress…
View article: Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination
Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination Open
Purpose: Immune responses to antigens originating in the central nervous system (CNS) are generally attenuated, as collateral damage can have devastating consequences. The significance of this finding for the efficacy of tumor-targeted imm…